An in situ enzyme-linked immunosorbent assay (ELISA), performed directly on fixed varicella-zoster virus-infected monolayers, was used to quantitate viral antigen, and by color reduction it was used to evaluate the activity of drugs against varicella-zoster virus. Color production in the ELISA (optical density) was directly related to the dose of input virus. Antigen representing 5 to 10 plaques could be detected 3 days after infection. The ELISA was specific and reproducible, as shown by absorption and repeat experiments, respectively. A color-reduction test by ELISA was compared with the conventional plaque-reduction assay for its ability to measure the antiviral activity of acyclovir, bromovinyldeoxyuridine, trifluorothymidine, and vidarabine against four strains of varicella-zoster virus. In all cases but one the 50% inhibitory doses were lower when measured by ELISA than by the plaque-reduction assay. This in situ ELISA color reduction method had the following advantages over the conventional plaque-reduction assay: (i) the endpoint was an objective measurement; (ii) there was less well-to-well variation; (iii) the assay was sensitive to changes in plaque size as well as plaque number; (iv) it was less labor intensive.
The plaque-reduction assay (PRA) is the method most often used to evaluate the activity of antiviral drugs against varicella-zoster virus (VZV) (2t 4-6, 9, 11, 13) . This assay has four problems. First, it is labor intensive. Second, the endpoint, counting plaques, is a subjective measurement which becomes less accurate when plaque morphology is indistinct. Third, cultures of slow-growing viruses, such as VZV, must be incubated for 3 to 5 days before plaques can be identified, and this period is longer for cytomegalovirus. Fourth, an antiviral agent may prevent plaque growth without completely preventing plaque formation (2, 4, 9, 11) , and this initial inhibitory effect on the rate of virus growth may not be detected by the PRA. This last problem can be overcome by using the infectious center assay, which measures the effect of an antiviral agent on the total number of infected cells in a culture. However, in the infectious center assay two series of cultures must be infected; therefore, it is even more laborious and time consuming than the PRA. As an alternative to the PRA, we used an enzyme-linked immunosorbent assay (ELISA) for evaluating, by color reduction, antiviral agents active against VZV. The ELISA was performed directly on fixed infected monolayers in microtiter plates, a technique previously used to type or identify viruses and to measure antibody or interferon activity (1, 8, 10, 14) .
MATERIALS AND METHODS Cells. Human embryonic lung fibroblasts (HELF; obtained from J. Waner, University of Oklahoma, Norman, Okla.) were used for experiments at passages 17 to 25.
Virus. Initial experiments were performed with cell-free VZV strain 502 which had been isolated and passaged many times in this laboratory. Other cell-associated strains of VZV (VZV-2, VZV-Ellen, and VZV-BW) were kindly supplied by were gifts from Burroughs Wellcome Co.; vidarabine (9-p-D-arabinofuranosyladenine) was a gift from Warner-Lambert Co.; and bromovinyldeoxyuridine [(E)-5-(2-bromovinyl)-2'-deoxyuridine] was a gift from Searle and Co. Stock solutions were made in distilled water and stored at 4°C. Dilutions were made in Dulbecco minimal essential medium containing penicillin (2 x 105 U/liter), kanamycin (100 mg/liter), and 2% untreated fetal calf serum (FCS) (Dul-2).
Infection of monolayers for evaluation of antiviral drugs by ELISA. The wells of a flat-bottomed microtiter plate (minitest III; Falcon) were seeded with 3 x 104 to 4 x 104 HELF in 0.2 ml of Dulbecco minimal essential medium containing 10% FCS (Dul-l0). The edge wells, which were not used in the experiments, were filled with water only. When the monolayers had become confluent, usually after 24 h, the medium was aspirated, and VZV, suspended in 0.1 ml of Dul-2, was added. After 2 h at 37°C, 0.1 ml of the test antiviral drug in Dul-2, at twice the desired final concentration, was added to each well. An inhibitor of adenosine deaminase was not incorporated into the medium in experiments involving vidarabine. The viral inocula ranged from 5 to 100 PFU, corresponding to a multiplicity of infection (12) . Each well received 0.1 ml of VZIG for 1 h at 37°C and was then washed five times with PBS-t-BSA. Peroxidase-conjugated goat antihuman immunoglobulin G (IgG) (Tago Inc., Burlingame, Calif.) diluted 1/2,000 in PBS-t containing 10% goat serun was then added (0.1 ml per well), and the plate was incubated for 2 h at 37°C. The wells were again washed five times with PBS-t, and 0.2 ml of substrate was added per well. The substrate was 1 mg/ml of the diammonium salt of 2,2'-azinobis(3-ethyl-benzthiazoline sulfonic acid) (Sigma Chemical Co., St 
RESULTS
The relationship between OD in the ELISA and the infecting dose of VZV is shown in Fig. 1 . The ELISA performed 3 days after infection could detect the antigen representing 5 to 10 plaques (data not shown) which was equivalent to an OD of 0.3 to 0.4. To obtain this sensitivity the lower limit of detection was defined as an OD greater than three standard deviations above the mean OD of the uninfected control monolayer (Fig. 1) . Since an input MOI of 1.25 x 10-3 was well within the linear portion of the curve, this input was chosen for subsequent assays of antiviral activity. In preliminary experiments, we demonstrated that the assay was more sensitive when the VZIG had been diluted in PBS-t-goat serum or in PBS-t-immunoglobulinpoor goat serum with 1% FCS than when it had been diluted in PBS-t-BSA or PBS-t-5% FCS. In these studies the concentration of fixative used and the duration of fixation were also important. As a Percent reduction = (AOD using VZIG absorbed with VZV-infected HELF subtracted from AOD using VZIG absorbed with uninfected HELF) divided by AOD using VZIG absorbed with uninfected HELF.
assay. Absorption with VZV-infected HELF, which would be expected to remove VZV-specific antibodies, resulted in a marked reduction in AOD ( Table 1) .
The ELISA and PRA methods for determining the activity of acyclovir against VZV-502 were compared in two experiments performed on different days (Fig. 2) . These experiments demonstrated that the ID50 determined by ELISA was lower than that by PRA and that each method was reproducible.
The ELISA method for antiviral activity allowed the demonstration of an inoculum effect for two of the four antiviral drugs tested (Table 2) . When an MOI of 1.25 x 10-3 was used, ID50s of trifluorothymidine and vidarabine were approximately twice the values obtained with an MOI of 0.125 x 10-3.
The ID50 of four antiviral drugs for four VZV isolates was determined by ELISA and PRA (Table 3 ). The ID50 deter- 4 0 a < . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Although the continuous time required to test a single isolate by the ELISA was longer than that required for the PRA (ca. 4.5 h versus 2.5 h), when multiple isolates were tested the time required increased only slightly with the ELISA, whereas that with the PRA increased in proportion to the number of isolates tested. DISCUSSION The in situ ELISA described here is the basis for a useful and reproducible method for determining the activity of antiviral drugs against VZV. It has several advantages over the PRA. The endpoint of the ELISA is an optical density reading which is an objective measurement. This contrasts with the endpoint of the PRA, in which recognition of VZV plaques may be difficult. In addition, in the PRA the antiviral agent often prevents an increase in plaque size without completely preventing plaque formation (2, 4, 9, 11; unpublished data). Thus, the PRA does not distinguish between plaques containing different numbers of infected cells. In fact, the ID50s were lower with the ELISA, probably because this assay measures the total amount of viral antigen in the monolayer (or plaque) and thereby corrects for differences in plaque size. The ID50s with both the ELISA and PRA obtained in this study were generally higher than those reported previously (2, 4-6, 9, 11, 13) . However, the published susceptibilities of different strains of VZV to the same drugs have varied widely (2, 4-6, 9, 11, 13) . VZV-Ellen is the only strain tested by us for which there are published data. We found the ID50 of this strain for acyclovir, measured by ELISA, to be 7 ,ug/ml, which is approximately 40-fold higher than that found by Biron and Elion (2) . The reason for this is unclear, but it is probably due to differences in the target cell used, a well-recognized reason for the variable susceptibilities of viruses to drugs (7) . The correlation between the in vitro antiviral activity of any drug, regardless of target cell type, and its in vivo activity is not well defined.
The in situ ELISA method is likely to be especially useful for slow-growing viruses since it can be performed before plaques are well developed. This report describes experiments performed 3 days after the monolayer had been infected with VZV, but we successfully performed the assay 2 days after infection. We have also used this method to quantitate cytomegalovirus antigen 3 days after infection and to determine the activity of dihydroxypropoxymethyl guanine against cytomegalovirus 6 days after infection (F. E. Berkowitz and M. J. Levin, unpublished data).
Using this ELISA we demonstrated a small inoculum effect with trifluorothymidine and vidarabine, a phenomenon previously described in relation to the activity of acyclovir against HSV and cytomegalovirus (7). The ELISA would facilitate the further study of the inoculum effect, as its working range of MOI is much higher than that of the PRA.
The in situ ELISA is associated with less variability than is the PRA, as demonstrated by lower coefficients of variation. This probably reflects the objectivity of the endpoint measurement and the number of replicates which can be easily included for each concentration of antiviral drug. Testing large numbers of VZV isolates (i.e., .3) will be easier and quicker by the ELISA than by the PRA, as should testing of slow-growing and fastidious viruses that form plaques poorly.
